Meeting
2018 ASCO Annual Meeting
Efficacy and safety of lurbinectedin (PM1183) in small cell lung cancer (SCLC): Results from a phase 2 study.
Authors
Jose Manuel Trigo Perez
Hospital Virgen de la Victoria, Malaga, Spain
Jose Manuel Trigo Perez , Alexandra Leary , Benjamin Besse , Daniel E. Castellano , Santiago Ponce Aix , Jennifer Arrondeau , Victor Moreno , Bernard Doger , Rafael Lopez , Ahmad Awada , Christiane Jungels , Martin David Forster , Valentina Boni , Pilar Lardelli , Mariano Siguero , Carmen Maria Kahatt , Arturo Soto-Matos , Rebecca Sophie Kristeleit
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02454972
Citation
J Clin Oncol 36, 2018 (suppl; abstr 8570)
DOI
10.1200/JCO.2018.36.15_suppl.8570
Abstract #
8570
Poster Bd #
176
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Efficacy and safety of lurbinectedin (PM1183) in Ewing sarcoma: Final results from a phase 2 study.
First Author: Vivek Subbiah
Poster
2022 ASCO Annual Meeting
Efficacy and safety of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer: Preliminary results of a phase 1 study.
First Author: Ying Cheng
Poster
2022 ASCO Annual Meeting
A phase 1/2 trial of lurbinectedin (L) in combination with pembrolizumab (P) in relapsed small cell lung cancer (SCLC): The LUPER study.
First Author: Antonio Calles
Poster
2020 ASCO Virtual Scientific Program
Pooled safety analysis of single-agent lurbinectedin versus topotecan (Results from a randomized phase III trial CORAIL and a phase II basket trial).
First Author: Alexandra Leary